BioNTech SE
$20.26B- Market cap
- $26.06B
- Debt
- +$2.68B
- Cash
- −$7.68B
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $26.06B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: BNTX stock price at discount vs FICO $103.76 current versus $134.28 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FICO's multiple
Implied fair value · at BNTX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BNTX FY 2025 (ended Dec 31, 2025) · FICO FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Capital structure 85% equity / 15% debt · EV / Revenue 11.78x · EV / EBITDA 25.32x
FICO carries the larger enterprise value at $23.46B against $20.26B; BNTX trades on the lower EV / Revenue multiple (6.07x vs 11.78x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
FAIR ISAAC CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
-1.98x
Net debt / EBITDA
Leverage against operating earnings
4.45x
3.58x
Cash and equivalents
Liquid reserves on the balance sheet
$7.68B
$134.14M
Total debt
Interest-bearing obligations outstanding
$2.68B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
BNTX vs MRNA
GILEAD SCIENCES, INC.
BNTX vs GILD
AMGEN INC
BNTX vs AMGN
REGENERON PHARMACEUTICALS, INC.
BNTX vs REGN
INCYTE CORP
BNTX vs INCY
VERTEX PHARMACEUTICALS INC / MA
BNTX vs VRTX
MSCI Inc.
BNTX vs MSCI
MOODYS CORP /DE/
BNTX vs MCO
SS&C Technologies Holdings Inc
BNTX vs SSNC
Verisk Analytics, Inc.
BNTX vs VRSK
EQUIFAX INC
BNTX vs EFX
$3.46B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.